1 min read
Add as a preferred source on GoogleEU Medicines Panel Issues Positive Opinion on Revolution Medicines’ Rasonque
The opinion covers second-line monotherapy for adults with metastatic pancreatic adenocarcinoma and was supported by Phase 3 study data.
On Oct. 15, the committee responsible for human medicines at the European Medicines Agency gave Revolution Medicines’ Rasonque (daraxonrasib) a positive opinion for adults with metastatic pancreatic adenocarcinoma.
The opinion covers the drug as a second-line monotherapy. It was supported by data from the Phase 3 RASolute study.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.